Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications.

Suppr

超能文献

作者信息

Soto Javier

出版信息

Pharmacoeconomics. 2006;24(5):519-20; author reply 520-2. doi: 10.2165/00019053-200624050-00008.

DOI:10.2165/00019053-200624050-00008

PMID:16706575

Abstract

摘要

相似文献

Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications.

Pharmacoeconomics. 2006;24(5):519-20; author reply 520-2. doi: 10.2165/00019053-200624050-00008.

Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.

Am J Ophthalmol. 2006 Aug;142(2):354; author reply 354-5. doi: 10.1016/j.ajo.2006.04.022.

Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications.

Pharmacoeconomics. 2006;24(3):251-64. doi: 10.2165/00019053-200624030-00005.

Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension.

Drugs Aging. 2006;23(1):39-47. doi: 10.2165/00002512-200623010-00004.

Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.

Am J Ophthalmol. 2006 Jan;141(1 Suppl):S15-21. doi: 10.1016/j.ajo.2005.06.030.

The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.

Curr Med Res Opin. 2006 May;22(5):897-905. doi: 10.1185/030079906X104687.

Comments on The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.

Curr Med Res Opin. 2006 Oct;22(10):1899-901; author reply 1901-2. doi: 10.1185/030079906X132569.

[The more favourable cost/effectiveness ratio of latanoprost vs bimatoprost and travoprost when using normally for treatment of glaucoma].

Arch Soc Esp Oftalmol. 2005 Jan;80(1):9-10; author reply 10. doi: 10.4321/s0365-66912005000100003.

Refill rates and budget impact of glaucoma lipid therapy: a retrospective database analysis.

Clin Drug Investig. 2007;27(12):819-25. doi: 10.2165/00044011-200727120-00003.

A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension.

Surv Ophthalmol. 2004 Nov-Dec;49(6):621-3; author reply 623-4. doi: 10.1016/j.survophthal.2004.08.017.

本文引用的文献

Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications.

Pharmacoeconomics. 2006;24(3):251-64. doi: 10.2165/00019053-200624030-00005.

Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.

Ophthalmology. 2006 Feb;113(2):239-46. doi: 10.1016/j.ophtha.2005.10.045.

Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data.

Am J Ophthalmol. 2006 Jan;141(1 Suppl):S28-33. doi: 10.1016/j.ajo.2005.09.011.

Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty.

Value Health. 2005 Jan-Feb;8(1):1-2. doi: 10.1111/j.1524-4733.2005.08101.x.

Compliance and persistency in glaucoma follow-up treatment.

Curr Opin Ophthalmol. 2005 Apr;16(2):114-21. doi: 10.1097/01.icu.0000156139.05323.26.

Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients.

Ophthalmology. 2005 Feb;112(2):262-6. doi: 10.1016/j.ophtha.2004.08.022.

A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension.

J Ocul Pharmacol Ther. 2004 Oct;20(5):383-92. doi: 10.1089/jop.2004.20.383.

24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.

Surv Ophthalmol. 2004 Mar;49 Suppl 1:S26-35. doi: 10.1016/j.survophthal.2003.12.017.

Patient persistency with topical ocular hypotensive therapy in a managed care population.

Am J Ophthalmol. 2004 Jan;137(1 Suppl):S3-12. doi: 10.1016/j.ajo.2003.10.035.

Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study.

Clin Ther. 2003 Apr;25(4):1172-85. doi: 10.1016/s0149-2918(03)80074-7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验